Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of CD19+ non-Hodgkin's lymphoma or chronic lymphocytic leukemia
• * Primary refractory or multiply relapsed (after at least 2 prior chemotherapy regimens) disease
• * Ineligible for bone marrow or peripheral blood stem cell transplantation
• PATIENT CHARACTERISTICS:
• Age:
• Over 18
• Performance status:
• ECOG 0-2
• Life expectancy:
• More than 3 months
• Hematopoietic:
• WBC greater than 3,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Absolute neutrophil count greater than 1,500/mm\^3
• Hepatic:
• Bilirubin less than 1.5 mg/dL
• Alkaline phosphatase less than 2 times normal
• SGPT less than 2 times normal
• Renal:
• Creatinine clearance greater than 50 mL/min
• Other:
• No human-anti-murine-antibody response to prior murine monoclonal antibodies
• No immunological or inflammatory disease (e.g., lupus erythematosus)
• No active serious infection
• No other serious medical condition that would limit survival to less than 2 years
• No other active malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix
• No psychiatric or addictive disorder that would preclude study
• Not pregnant or nursing
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Prior immunotherapy allowed
• Chemotherapy:
• See Disease Characteristics
• No concurrent chemotherapy
• Endocrine therapy:
• Concurrent steroids for adrenal failure or adverse reactions to study drug allowed
• Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for diabetes) allowed
• Radiotherapy:
• Not specified
• Surgery:
• Not specified